TQB2102(首创HER2双表位抗体偶联药物)的临床前特征及晚期实体瘤I期结果
TQB2102是靶向HER2 ECD2和ECD4的双表位抗体偶联药物,偶联拓扑异构酶I抑制剂。这项在中国12中心开展的I期首次人体试验纳入195例晚期实体瘤患者,未发生DLT且未达MTD,RP2D为6.0和7.5 mg/kg每3周一次,安全性可控,在HER2阳性及HER2低表达乳腺癌等瘤种中观察到初步抗肿瘤活性,HER2低表达转移性乳腺癌III期试验已启动。
要点
- TQB2102在晚期实体瘤中未发生DLT、未达MTD,RP2D为6.0和7.5 mg/kg每3周一次。
- 常见≥3级治疗相关不良事件为中性粒细胞计数降低(23.2%)等,药物相关间质性肺病仅0.5%。
- HER2阳性转移性乳腺癌ORR为52.4%,HER2低表达转移性乳腺癌ORR为47.2%。
核心结论
- TQB2102在晚期实体瘤中安全性可控并显示初步抗肿瘤活性,HER2低表达转移性乳腺癌III期试验已启动。
研究设计与样本
- I期、多中心、首次人体试验,中国12中心,纳入晚期实体瘤患者,每3周静脉给药。
- 剂量递增阶段为1.5、3.0、4.5、6.0、7.5和9.0 mg/kg,剂量扩展阶段为6.0和7.5 mg/kg。
- 主要终点为安全性及确定DLT、MTD和RP2D,共纳入195例患者。
主要发现
- 未发生DLT,未达到MTD,RP2D选择为6.0 mg/kg和7.5 mg/kg每3周一次。
- 最常见的≥3级治疗相关不良事件为中性粒细胞计数降低(23.2%)、白细胞计数降低(10.8%)、贫血(8.8%)和淋巴细胞计数降低(8.2%)。
- 仅1例患者(0.5%)发生药物相关间质性肺病。
- HER2阳性实体瘤ORR:转移性乳腺癌52.4%、结直肠癌38.7%、胃/胃食管结合部腺癌40.0%;HER2低表达转移性乳腺癌ORR为47.2%。
- HER2阳性和HER2低表达转移性乳腺癌脑转移患者的ORR分别为70.0%和50.0%。
关键数值与推荐
- RP2D为6.0 mg/kg和7.5 mg/kg每3周一次。
- HER2阳性转移性乳腺癌ORR为52.4%,HER2低表达转移性乳腺癌ORR为47.2%。
- HER2阳性结直肠癌ORR为38.7%,HER2阳性胃/胃食管结合部腺癌ORR为40.0%。
临床怎么用
- TQB2102每3周静脉给药,RP2D为6.0或7.5 mg/kg,需监测血细胞计数和间质性肺病。
- 在HER2阳性及HER2低表达转移性乳腺癌中观察到初步疗效,HER2低表达转移性乳腺癌III期试验已启动。
局限性
- 为I期首次人体试验,样本量有限,疗效为初步结果。
- 入组以转移性乳腺癌、结直肠癌和胃/胃食管结合部腺癌为主,其他瘤种数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: TQB2102 is a next-generation biparatopic antibody-drug conjugate targeting human epidermal growth factor receptor 2 (HER2) extracellular domain 2 (ECD2) and ECD4 epitopes that is conjugated to a topoisomerase I inhibitor via an enzyme-cleavable linker. This study evaluated the safety, efficacy, and pharmacokinetics of TQB2102 in patients with advanced solid tumors. PATIENTS AND METHODS: In this phase I, multicenter, first-in-human trial, patients with advanced solid tumors were recruited from 12 centers in China. Eligible patients received intravenous TQB2102 once every 3 weeks. This phase I trial included a dose-escalation phase (1.5, 3.0, 4.5, 6.0, 7.5, and 9.0 mg/kg) and a dose-expansion phase (6.0 and 7.5 mg/kg). The primary endpoints were to assess the safety and determine the dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of TQB2102. RESULTS: Between 8 March 2023 and 1 February 2025, 195 patients were enrolled, mainly those having metastatic breast cancer (MBC, n = 80), colorectal cancer (CRC, n = 37), and gastric/gastroesophageal junction (G/GEJ) adenocarcinoma (n = 37). No DLTs occurred, and the MTD was not reached. The RP2D was selected as 6.0 mg/kg and 7.5 mg/kg every 3 weeks. The most common grade ≥3 treatment-related adverse events were decreased neutrophil count (23.2%), decreased white blood cell count (10.8%), anemia (8.8%), and decreased lymphocyte count (8.2%). Only one patient (0.5%) had drug-related interstitial lung disease. The objective response rate (ORR) was attained in patients with HER2-positive solid tumors, including MBC at 52.4%, CRC at 38.7%, and G/GEJ adenocarcinoma at 40.0%. Notably, patients with HER2-low MBC achieved an ORR of 47.2%. The ORRs were 70.0% and 50.0% in HER2-positive and HER2-low MBC patients with brain metastases. CONCLUSIONS: TQB2102 demonstrates a manageable safety profile and preliminary antitumor activity in advanced solid tumors. A phase III trial in patients with HER2-low MBC has been initiated.
引用
- Ruan DY, Lin SY, Huang JJ, et al. Preclinical characterization and phase I results of TQB2102, a first-in-class HER2 biparatopic antibody-drug conjugate, in patients with advanced solid tumors. Ann Oncol. 2026. PMID: 42142622. doi:10.1016/j.annonc.2026.05.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。